filmov
tv
Ivermectin trial, Oxford University

Показать описание
Ivermectin Arm of PRINCIPLE Trial Put on Hold?
MedPage Today, Merck
"concluded that the probability of ivermectin providing a potentially safe and efficacious treatment option for SARS-CoV-2 infection is low and have prioritized internal efforts towards the development of alternate candidates that provide a higher probability of success for the treatment of COVID-19."
"If clinical data emerge providing definitive evidence for a positive benefit-risk assessment of the use of ivermectin in COVID-19, we stand ready to provide our expertise and resources as needed,"
Ivermectin, PRINCIPLE trial
Professor Chris Butler, from the University Oxford’s Nuffield Department of Primary Care Health Sciences,
Joint Chief Investigator of the PRINCIPLE trial, said,
‘Ivermectin is readily available globally,
has been in wide use for many other infectious conditions so it’s a well-known medicine with a good safety profile,
and because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries.
International Standard Randomised Controlled Trial Number
When is the study starting and how long is it expected to run for?
March 2020 to September 2022
Favipiravir
Ivermectin
A double blind trial
Independent Data Monitoring and Safety Committee
Will pick up a signal for futility, superiority, or safety
Will let the Trial Steering Committee know
Then a final analysis can be conducted, followed by the release of results and data
MedPage Today, Merck
"concluded that the probability of ivermectin providing a potentially safe and efficacious treatment option for SARS-CoV-2 infection is low and have prioritized internal efforts towards the development of alternate candidates that provide a higher probability of success for the treatment of COVID-19."
"If clinical data emerge providing definitive evidence for a positive benefit-risk assessment of the use of ivermectin in COVID-19, we stand ready to provide our expertise and resources as needed,"
Ivermectin, PRINCIPLE trial
Professor Chris Butler, from the University Oxford’s Nuffield Department of Primary Care Health Sciences,
Joint Chief Investigator of the PRINCIPLE trial, said,
‘Ivermectin is readily available globally,
has been in wide use for many other infectious conditions so it’s a well-known medicine with a good safety profile,
and because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries.
International Standard Randomised Controlled Trial Number
When is the study starting and how long is it expected to run for?
March 2020 to September 2022
Favipiravir
Ivermectin
A double blind trial
Independent Data Monitoring and Safety Committee
Will pick up a signal for futility, superiority, or safety
Will let the Trial Steering Committee know
Then a final analysis can be conducted, followed by the release of results and data
Комментарии